Addressing the Challenges of Bioconjugate Medicines - Abzena

Addressing the Challenges of Bioconjugate Medicines

Authors: Mark Frigerio, Ph.D* and Fuan Kang, Ph.D.

Publication: ADC Review

First published: 8 April 2020

The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the large unmet medical need currently unattainable from current therapeutic approaches. As the field of bioconjugation develops, and the recent spate of antibody-drug conjugates (ADCs) approvals continues, the resulting knock-on effects for delivering a wider range of bioconjugated molecules will also continue to expand in utility.

Full paper available at:

Interested in our services? Get In Touch